BRPI0509828B1 - Composição de estimulação da resposta imune compreendendo nanopartículas com base em éter maleico vinil metil e copolímero anidrido - Google Patents

Composição de estimulação da resposta imune compreendendo nanopartículas com base em éter maleico vinil metil e copolímero anidrido Download PDF

Info

Publication number
BRPI0509828B1
BRPI0509828B1 BRPI0509828-9A BRPI0509828A BRPI0509828B1 BR PI0509828 B1 BRPI0509828 B1 BR PI0509828B1 BR PI0509828 A BRPI0509828 A BR PI0509828A BR PI0509828 B1 BRPI0509828 B1 BR PI0509828B1
Authority
BR
Brazil
Prior art keywords
nanoparticles
copolymer
immune response
antigen
composition
Prior art date
Application number
BRPI0509828-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Juan Manuel Irache Garreta
Carlos Gamazo De La Rasilla
Maria Luisa Sanz Larruga
Marta Ferrer Puga
Beatriz SAN ROMÁN ABERASTURI
Hesham H. A. Salman
Sara Gómez Martínez
Javier Ochoa Repáraz
Original Assignee
Universidad De Navarra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De Navarra filed Critical Universidad De Navarra
Publication of BRPI0509828A publication Critical patent/BRPI0509828A/pt
Publication of BRPI0509828B1 publication Critical patent/BRPI0509828B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BRPI0509828-9A 2004-04-29 2005-04-28 Composição de estimulação da resposta imune compreendendo nanopartículas com base em éter maleico vinil metil e copolímero anidrido BRPI0509828B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200401023 2004-04-29
ES200401023A ES2246695B1 (es) 2004-04-29 2004-04-29 Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
PCT/ES2005/000225 WO2005105056A1 (es) 2004-04-29 2005-04-28 Composición estimuladora de la respuesta inmunitaria que comprende nanopartículas a base de un copolímero de metil vinil éter y anhídrido maleico

Publications (2)

Publication Number Publication Date
BRPI0509828A BRPI0509828A (pt) 2007-11-27
BRPI0509828B1 true BRPI0509828B1 (pt) 2021-07-13

Family

ID=35241413

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509828-9A BRPI0509828B1 (pt) 2004-04-29 2005-04-28 Composição de estimulação da resposta imune compreendendo nanopartículas com base em éter maleico vinil metil e copolímero anidrido

Country Status (12)

Country Link
US (1) US8895067B2 (https=)
EP (1) EP1752141B1 (https=)
JP (1) JP4932704B2 (https=)
CN (1) CN1976687B (https=)
AU (1) AU2005237269B2 (https=)
BR (1) BRPI0509828B1 (https=)
CA (1) CA2564974C (https=)
DE (1) DE602005015441D1 (https=)
ES (2) ES2246695B1 (https=)
MX (1) MXPA06012527A (https=)
RU (1) RU2379028C2 (https=)
WO (1) WO2005105056A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246695B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US7396886B2 (en) * 2005-06-21 2008-07-08 Isp Investments Inc. Process for making copolymers of maleic anhydride and alkyl vinyl ether of high specific viscosity
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
ES2286951B1 (es) * 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
EP2630966B1 (en) * 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
JP2010077057A (ja) * 2008-09-25 2010-04-08 Kagoshima Univ 抗食物アレルギーワクチン
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US10184937B2 (en) * 2009-03-31 2019-01-22 United Arab Emirates University Minimally invasive assessment of IgE mediated allergy
CA2762653A1 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
EP2510930A1 (en) * 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
ES2369949B1 (es) * 2011-05-19 2013-08-13 Universidade De Santiago De Compostela Microesferas poliméricas como adyuvantes en la producción de vacunas frente a parásitos escuticociliados de peces.
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
WO2013192532A2 (en) 2012-06-21 2013-12-27 Northwestern University Peptide conjugated particles
CN105188741A (zh) 2013-04-03 2015-12-23 阿勒丁医疗公司 新型纳米颗粒组合物
US9668970B2 (en) * 2013-12-02 2017-06-06 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US10272038B2 (en) 2013-12-02 2019-04-30 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
WO2016087340A1 (en) 2014-12-01 2016-06-09 Innoup Farma, S.L. Nanoparticles for encapsulating compounds, the preparation and uses thereof
CN112057610A (zh) * 2019-06-10 2020-12-11 中国科学院宁波材料技术与工程研究所 一种超小纳米免疫增强剂-抗原复合纳米粒子及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
GB8601100D0 (en) 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
SE8900422D0 (sv) 1989-02-08 1989-02-08 Pharmacia Ab Tvaerbundna hyaluronatgeler samt foerfarande foer framstaellning av dessa
IT1247472B (it) 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
EP0544259A1 (en) 1991-11-27 1993-06-02 Lignyte Co., Ltd. Water insoluble biocompatible hyaluronic and polyion complex and method of making the same
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US20010053359A1 (en) 1994-07-26 2001-12-20 Peter Watts Drug delivery composition for the nasal administration of antiviral agents
AU3159595A (en) 1994-08-30 1996-03-22 Hyal Pharmaceutical Corporation Hyaluronic acid and derivatives for modulation of cellular activity
ES2098188B1 (es) 1995-05-11 1997-12-16 Univ Santiago Compostela Desarrollo de nanoparticulas a base de polimeros hidrofilicos.
ES2098189B1 (es) 1995-05-23 1997-12-16 Fernandez Arenas Antonio Sistema para la toma de impresiones destinadas a la confeccion de protesis dentales implantosoportadas y medios para su realizacion.
ES2177592T3 (es) 1995-07-05 2002-12-16 Europ Economic Community Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos.
WO1997004747A1 (en) 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
US7276251B2 (en) 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
ES2114502B1 (es) 1996-07-29 1999-07-01 Univ Santiago Compostela Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas.
AU9799198A (en) 1997-10-09 1999-05-03 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
DE19810965A1 (de) 1998-03-13 1999-09-16 Aventis Res & Tech Gmbh & Co Nanopartikel, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2777193B1 (fr) 1998-04-14 2001-06-08 Coletica Particule a groupement hydroxamique chelatante d'ions metalliques et leur utilisation en cosmetique ou en pharmacie
FR2777895A1 (fr) 1998-04-28 1999-10-29 Debio Rech Pharma Sa Polymere sequence non-reticule,procede pour sa preparation, et ses utilisations
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
JP4526708B2 (ja) 1998-09-01 2010-08-18 メリオン リサーチ スリー リミテッド 細胞を媒介した免疫応答を誘導する方法及びそのための非経口ワクチン製剤
IN191203B (https=) 1999-02-17 2003-10-04 Amarnath Prof Maitra
AU4476600A (en) 1999-04-22 2000-11-10 Vanderbilt University Polymeric encapsulation system promoting angiogenesis
US6645525B1 (en) 1999-06-23 2003-11-11 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
US20020009466A1 (en) 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
PT1223990E (pt) 1999-10-15 2004-12-31 Fidia Advanced Biopolymers Srl Formulacoes de acido hialuronico para administracao de proteinas osteogenicas
US6743446B2 (en) 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
EP1311288A1 (en) * 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
WO2001078687A1 (en) 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
WO2001082724A2 (en) 2000-05-03 2001-11-08 Natural As Compositions containing aminopolysaccharides and negatively charged polysaccharides
US6773695B2 (en) * 2000-10-05 2004-08-10 Mannkind Corporation Modulation of allergic response
KR100375299B1 (ko) 2000-10-10 2003-03-10 주식회사 엘지생명과학 히알루론산의 가교결합형 아마이드 유도체와 이의 제조방법
ES2178961B1 (es) * 2001-03-06 2004-07-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.
CA2469718A1 (en) * 2001-12-10 2003-06-19 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
ES2221530B1 (es) 2002-07-19 2006-02-16 Universidad De Santiago De Compostela Nanoparticulas para la administracion de ingredientes activos,procedimiento para la elaboracion de dichas particulas y composicion que las contienen.
US7273327B2 (en) 2003-06-20 2007-09-25 Colgate-Palmolive Company Oral care implement
RU2370500C2 (ru) 2003-08-12 2009-10-20 Октафарма Аг Способ очистки раствора альфа-1-антитрипсина
ES2246695B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.

Also Published As

Publication number Publication date
JP4932704B2 (ja) 2012-05-16
DE602005015441D1 (de) 2009-08-27
ES2246695B1 (es) 2007-05-01
US20070224225A1 (en) 2007-09-27
CN1976687B (zh) 2010-05-05
AU2005237269A1 (en) 2005-11-10
EP1752141B1 (en) 2009-07-15
WO2005105056A1 (es) 2005-11-10
CN1976687A (zh) 2007-06-06
MXPA06012527A (es) 2007-04-10
CA2564974A1 (en) 2005-11-10
RU2379028C2 (ru) 2010-01-20
AU2005237269B2 (en) 2011-08-11
CA2564974C (en) 2013-07-02
EP1752141A1 (en) 2007-02-14
ES2329598T3 (es) 2009-11-27
RU2006142094A (ru) 2008-06-20
US8895067B2 (en) 2014-11-25
ES2246695A1 (es) 2006-02-16
BRPI0509828A (pt) 2007-11-27
JP2007534728A (ja) 2007-11-29

Similar Documents

Publication Publication Date Title
BRPI0509828B1 (pt) Composição de estimulação da resposta imune compreendendo nanopartículas com base em éter maleico vinil metil e copolímero anidrido
Kang et al. Pluronic® F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin
Florindo et al. The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-ɛ-caprolactone-based nanoparticles
JP2015078204A (ja) 免疫調節剤粒子および処置方法
Jiang et al. In vitro study of the immune stimulating activity of an athrophic rhinitis vaccine associated to chitosan microspheres
US9585955B2 (en) Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
US10004790B2 (en) Nanospheres encapsulating bioactive material and method for formulation of nanospheres
Florindo et al. New approach on the development of a mucosal vaccine against strangles: systemic and mucosal immune responses in a mouse model
Afshari et al. Immunogenicity evaluating of the SLNs-alginate conjugate against Pseudomonas aeruginosa
WO2007138135A1 (es) Nanopartículas bioadhesivas para la administración de moléculas biológicamente activas
Keegan et al. Biomimetic design in microparticulate vaccines
RU2428991C1 (ru) Сополимеры гетероцепных алифатических поли-n-оксидов, вакцинирующие и лекарственные средства на их основе
Taghizadeh et al. Nasal administration of M2e/CpG-ODN encapsulated in n-trimethyl chitosan (TMC) significantly increases specific immune responses in a mouse model
BR112014017923B1 (pt) Método para a produção de uma composição
RU2545714C1 (ru) Способ получения адъюванта для вирусных вакцин
US20190060426A1 (en) Method and apparatus for microneedle transdermal delivery
Florindo et al. Surface modified polymeric nanoparticles for immunisation against equine strangles
RU2545717C1 (ru) Способ получения адъюванта для вакцин
Saraf et al. Acid resilience oral mucosal delivery for vaccination against Hepatitis-B
WO2020099869A1 (en) Nanoparticles and uses thereof
Măruţescu et al. Nanomedicine progress in prevention, detection, and treatment of tuberculosis

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: UNIVERSIDAD DE NAVARRA (ES)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/04/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2877 DE 24/02/2026 POR TER SIDO INDEVIDA.